Lipid Nanoparticle– tag –
-
mRNA-LNP Technology Proven Effective in COVID-19 Vaccines, Bolstering Drug Delivery Customization Capabilities
Inside Therapeutics USA Overview This article discusses the revolutionary potential of mRNA-lipid nanoparticles (LNPs) in pharmaceuticals, vaccines, and therapeutics. LNPs are highlighted as the most clinically advanced platform for mRNA... -
Cleavable Crosslinking of Cholesterol Stabilizes Anionic mRNA Lipid Nanoparticles, Enhancing Splenic mRNA Expression and Transfection Efficiency
ACS Applied Materials & Interfaces (ACS Publications) USA Overview This study introduces a novel method to stabilize anionic mRNA lipid nanoparticles (LNPs) through cleavable crosslinking of cholesterol, addressing stability limitations ... -
Cytokine Co-Presentation on Targeted Lipid Nanoparticles Enhances In Vivo T Cell Engineering: IL-7 Co-Presentation Biases Functional mRNA Transfection Towards Splenic T Cells
PubMed (bioRxiv) Unknown Overview This research describes an enhanced lipid nanoparticle (LNP) design that co-presents interleukin-7 (IL-7) with anti-CD3 and anti-CD28 antibodies. This novel LNP significantly improves particle uptake and... -
Galmed Pioneers Cardiac-Targeted LNP for Fibrosis, Repurposing Aramchol with Precision
GlobeNewswire via Galmed Israel Overview Galmed, in collaboration with Barcode Nanotech, has engineered a novel lipid nanoparticle (LNP) formulation for its SCD1 inhibitor, Aramchol. This innovation enables precise, heart-targeted delive... -
Oregon State University Develops Novel Sugar-Coated Nanoparticle Therapy for Glioblastoma: Boosting Mouse Survival by 50%
Oregon State University via Medical Xpress USA Overview Researchers at Oregon State University have developed a new experimental glioblastoma treatment using sugar-coated nanoparticles to deliver genetic instructions that restore a tumor... -
Nava Therapeutics Raises $89 Million for Lipid Nanoparticle (LNP) Platform: Innovating RNA Therapeutic Delivery
Endpoints News USA Overview Nava Therapeutics announced the completion of an $89 million Series A funding round to advance its lipid nanoparticle (LNP) platform, specialized in efficient RNA-based therapeutic delivery. This substantial f... -
Clarivate Releases ‘Drugs to Watch in 2026’ List: AI Drug Discovery and DDS Technologies Highlighted as Promising Candidates
Clarivate UK Overview Clarivate released its mid-year 'Drugs to Watch' list for 2026, emphasizing that AI drug discovery and innovative drug delivery system (DDS) technologies are key trends driving the future market. The list includes A... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv... -
Cytiva Webinar Unpacks mRNA-LNP Innovations Driving Next-Gen Cancer Vaccines and Scalable Manufacturing
Cytiva Sweden Overview A forthcoming Cytiva webinar is set to explore the latest advancements in mRNA-LNP (Lipid Nanoparticle) technology, critical for accelerating next-generation cancer vaccine development. The discussion will focus on... -
GEMMABio Secures ARPA-H Funding to Advance LNP-Delivered mRNA Base Editing Strategy for Rare Liver Diseases
BioSpace USA Overview GEMMABio announced securing ARPA-H funding to develop four mRNA-encoded base editing products delivered via lipid nanoparticles (LNPs) in collaboration with Profluent. This innovative strategy targets four pathogeni...
